• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙酰-L-肉碱对间歇性跛行患者生活质量的影响。

Effect of propionyl-L-carnitine on quality of life in intermittent claudication.

作者信息

Brevetti G, Perna S, Sabba C, Martone V D, Di Iorio A, Barletta G

机构信息

Department of Medicine, University Federico II, Naples, Italy.

出版信息

Am J Cardiol. 1997 Mar 15;79(6):777-80. doi: 10.1016/s0002-9149(96)00867-3.

DOI:10.1016/s0002-9149(96)00867-3
PMID:9070558
Abstract

A double-blind, dose titration study was designed to assess the efficacy of propionyl-L-carnitine in intermittent claudication. The effect on walking capacity was described in a previous article. This study reports on the effect on quality of life, assessed by the McMaster Health Index Questionnaire (MHIQ). After 24 weeks of treatment, the global MHIQ score did not show any difference from baseline in patients randomized to placebo (n = 102). Conversely, it increased from 0.59 +/- 0.12 to 0.64 +/- 0.12 in those taking propionyl-L-carnitine (n = 85). Analysis of variance showed a significant difference between treatments (p = 0.018). Stepwise multiple regression analysis identified baseline maximal walking capacity (cutoff point 250 m) as a predictor of treatment outcome. In patients walking < 250 m, propionyl-L-carnitine significantly improved physical function (p = 0.027), emotional function (p = 0.002), and global MHIQ score (p = 0.002) compared with placebo. Also, for maximal walking capacity, group difference significantly favored propionyl-L-carnitine (p = 0.009). In patients with baseline maximal walking capacity > or = 250 m, propionyl-L-carnitine did not affect the MHIQ scores, nor improve walking performance. These data indicate that propionyl-L-carnitine exerts beneficial effects on quality of life and walking performance in patients with more severely limited walking capacity.

摘要

一项双盲、剂量滴定研究旨在评估丙酰-L-肉碱治疗间歇性跛行的疗效。之前的一篇文章描述了其对步行能力的影响。本研究报告了通过麦克马斯特健康指数问卷(MHIQ)评估的对生活质量的影响。治疗24周后,随机分配到安慰剂组的患者(n = 102)的MHIQ总体评分与基线相比无差异。相反,服用丙酰-L-肉碱的患者(n = 85)的评分从0.59±0.12提高到了0.64±0.12。方差分析显示治疗组间存在显著差异(p = 0.018)。逐步多元回归分析确定基线最大步行能力(临界点250米)为治疗结果的预测指标。在最大步行距离小于250米的患者中,与安慰剂相比,丙酰-L-肉碱显著改善了身体功能(p = 0.027)、情绪功能(p = 0.002)和MHIQ总体评分(p = 0.002)。此外,对于最大步行能力,组间差异显著有利于丙酰-L-肉碱(p = 0.009)。在基线最大步行能力≥250米的患者中,丙酰-L-肉碱未影响MHIQ评分,也未改善步行表现。这些数据表明,丙酰-L-肉碱对步行能力严重受限的患者的生活质量和步行表现具有有益作用。

相似文献

1
Effect of propionyl-L-carnitine on quality of life in intermittent claudication.丙酰-L-肉碱对间歇性跛行患者生活质量的影响。
Am J Cardiol. 1997 Mar 15;79(6):777-80. doi: 10.1016/s0002-9149(96)00867-3.
2
European multicenter study on propionyl-L-carnitine in intermittent claudication.欧洲关于丙酰-L-肉碱治疗间歇性跛行的多中心研究。
J Am Coll Cardiol. 1999 Nov 1;34(5):1618-24. doi: 10.1016/s0735-1097(99)00373-3.
3
Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.丙酰-L-肉碱治疗间歇性跛行:双盲、安慰剂对照、剂量滴定、多中心研究。
J Am Coll Cardiol. 1995 Nov 15;26(6):1411-6. doi: 10.1016/0735-1097(95)00344-4.
4
Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.丙酰-L-肉碱可改善间歇性跛行患者的运动能力和功能状态。
Am J Med. 2001 Jun 1;110(8):616-22. doi: 10.1016/s0002-9343(01)00704-5.
5
Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.监测下运动对周围动脉疾病性跛行患者的丙酰肉碱作用。
J Cardiopulm Rehabil Prev. 2011 Mar-Apr;31(2):125-32. doi: 10.1097/HCR.0b013e3181f1fd65.
6
A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication.系统评价评估肉碱补充剂在改善间歇性跛行患者行走表现方面的有效性。
Atherosclerosis. 2013 Jul;229(1):1-9. doi: 10.1016/j.atherosclerosis.2013.03.004. Epub 2013 Mar 15.
7
A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.一项关于丙酰肉碱片治疗间歇性跛行的疗效和安全性评估的研究。
Thromb Res. 2013 Oct;132(4):427-32. doi: 10.1016/j.thromres.2013.08.005. Epub 2013 Aug 14.
8
Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.丙酰左旋肉碱:间歇性跛行和外周动脉疾病。
Expert Opin Pharmacother. 2009 Nov;10(16):2697-707. doi: 10.1517/14656560903215871.
9
Propionyl-L-carnitine.丙酰-L-肉碱
Drugs Aging. 1998 Mar;12(3):243-8; discussion 249-50. doi: 10.2165/00002512-199812030-00006.
10
Propionyl-L-carnitine for intermittent claudication.用于间歇性跛行的丙酰-L-肉碱
J Fam Pract. 1997 Jun;44(6):533-4.

引用本文的文献

1
Effect of Dietary Supplements Which Upregulate Nitric Oxide on Walking and Quality of Life in Patients with Peripheral Artery Disease: A Meta-Analysis.上调一氧化氮的膳食补充剂对外周动脉疾病患者步行能力和生活质量的影响:一项荟萃分析。
Biomedicines. 2023 Jun 29;11(7):1859. doi: 10.3390/biomedicines11071859.
2
Propionyl-L-carnitine for intermittent claudication.丙酰肉碱治疗间歇性跛行。
Cochrane Database Syst Rev. 2021 Dec 26;12(12):CD010117. doi: 10.1002/14651858.CD010117.pub2.
3
[Neurolitic block of the lumbar sympathetic chain improves chronic pain in a patient with critical lower limb ischemia].
[腰交感神经链神经松解术改善严重下肢缺血患者的慢性疼痛]
Braz J Anesthesiol. 2018 Jan-Feb;68(1):100-103. doi: 10.1016/j.bjan.2015.03.007. Epub 2016 Jan 23.
4
Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication.丙酰肉碱与己酮可可碱:改善间歇性跛行患者的步行能力。
Clin Drug Investig. 2002 Nov;22(Suppl 1):1-6. doi: 10.2165/00044011-200222001-00001.
5
Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.肉碱及酰基肉碱:药代动力学、药理学和临床方面。
Clin Pharmacokinet. 2012 Sep 1;51(9):553-72. doi: 10.1007/BF03261931.
6
Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.L-肉碱类似物在心脏代谢紊乱临床应用中的重要更新。
Vasc Health Risk Manag. 2011;7:169-76. doi: 10.2147/VHRM.S14356. Epub 2011 Mar 28.
7
Assessment of functional status and quality of life in claudication.跛行患者的功能状态和生活质量评估。
J Vasc Surg. 2011 May;53(5):1410-21. doi: 10.1016/j.jvs.2010.11.092. Epub 2011 Feb 18.
8
Drug treatment of intermittent claudication.间歇性跛行的药物治疗
Drugs. 2004;64(15):1657-70. doi: 10.2165/00003495-200464150-00004.
9
Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatment.间歇性跛行:治疗的药物经济学与生活质量方面
Pharmacoeconomics. 2002;20(3):169-81. doi: 10.2165/00019053-200220030-00003.
10
Quality-of-life assessment in comparative therapeutic trials and causal structure considerations in peripheral occlusive arterial disease.
Pharmacoeconomics. 2001;19(2):121-30. doi: 10.2165/00019053-200119020-00002.